Merck v. USV: Sugammadex Patent Dispute Resolved via Federal Circuit Res Judicata
Merck Sharp & Dohme, B.V. filed suit against USV Pvt., Ltd. in the District of New Jersey over reissue patent USRE044733E, covering Bridion® (sugammadex) injection used for neuromuscular blockade reversal. The case closed in 224 days after the court applied a Federal Circuit affirmance as res judicata, binding both parties to the outcome of a prior consolidated action without a fresh merits determination.
Res Judicata Forecloses Re-litigation of Sugammadex Patent Expiry
On January 23, 2025, Merck Sharp & Dohme, B.V. initiated Case No. 2:25-cv-00694 in the District of New Jersey against Indian generic manufacturer USV Pvt., Ltd., asserting infringement of reissue patent USRE044733E. The patent in suit covers sugammadex injection — marketed by Merck as Bridion® — a selective relaxant binding agent widely used in anaesthesia to reverse neuromuscular blockade induced by rocuronium or vecuronium bromide.
The case closed on September 4, 2025, via consolidation with a prior related action. The court entered a Modified Final Judgment, declaring that the Federal Circuit’s affirmance of the Final Judgment in the Consolidated Action operates as res judicata against both Merck and USV in this proceeding. Critically, both parties were also held bound by the Federal Circuit’s determination of the ‘733 patent’s expiration date, foreclosing any independent re-litigation of that issue. Each party was directed to bear its own fees and costs.
At 224 days from filing to closure, the resolution is notably swift for pharmaceutical patent litigation, consistent with a procedural rather than merits-based termination. The public record does not disclose the specific terms of the Consolidated Action’s final judgment or when the ‘733 patent expires, though the court’s res judicata ruling suggests USV had previously been a party — or was treated as bound — in that earlier proceeding. The absence of fee-shifting suggests neither party was found to have litigated in bad faith.
Filing to Case Consolidated in 224 days
224 days — faster than the median ANDA/pharma patent district court case, which typically runs 2–4 years to trial
Consolidation and res judicata: what the court’s ruling means for both parties
Res judicata binds USV to a prior Federal Circuit ruling
The court applied res judicata (claim preclusion) arising from the Federal Circuit’s affirmance of a Final Judgment in a Consolidated Action. This doctrine prevents re-litigation of claims or issues already conclusively decided between the same parties. USV is bound by that prior outcome — including the Federal Circuit’s determination of the ‘733 patent’s expiration date — without the court conducting a fresh merits analysis in this proceeding.
Claim preclusion appliedMerck secures binding expiration date without re-litigating
For Merck, the consolidation outcome is commercially significant: the Federal Circuit-affirmed expiration date of USRE044733E is now binding on USV in this action, reinforcing Merck’s ability to enforce Bridion® exclusivity through the patent term. Merck avoided the cost and risk of a full trial, though the absence of a fee award means it absorbs its own litigation costs. The reissue patent’s enforceability is not directly undermined by this procedural resolution.
Patent term binding on USVUSV’s independent challenge is foreclosed by prior proceedings
USV is precluded from relitigating the expiration date of the ‘733 patent or the merits resolved in the Consolidated Action. This effectively closes the door on any separate invalidity or non-infringement argument that was — or could have been — raised in the prior proceedings. USV retains the ability to launch only after the Federal Circuit-affirmed expiration date, and each party bearing its own costs suggests no finding of frivolous conduct on USV’s part.
Re-litigation foreclosedSugammadex genericisation timeline anchored by Federal Circuit ruling
The binding expiration date determination means the market entry window for generic sugammadex competitors is now anchored in Federal Circuit precedent, not subject to case-by-case re-litigation by each ANDA filer. Other generics facing similar Bridion® patent disputes should treat the Federal Circuit-affirmed expiration date as the operative baseline. This reduces uncertainty for branded and generic manufacturers planning commercial strategies around sugammadex exclusivity.
Market entry timeline fixedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Merck Sharp & Dohme, B.V. | Individual | Pharmaceutical innovator — holder of USRE044733E covering sugammadex (Bridion®) injectionSearch in Eureka ↗ |
| Defendant | USV Pvt., Ltd. | Company | USV Pvt., Ltd. — Indian generic pharmaceutical manufacturer seeking U.S. market entry with sugammadex injectionSearch in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Merck Sharp & Dohme, B.V.Search in Eureka ↗ |
| Plaintiff counsel | Sarah A. Geers | Attorney | Counsel for Merck Sharp & Dohme, B.V.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Merck Sharp & Dohme, B.V.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Merck Sharp & Dohme, B.V.Search in Eureka ↗ |
| Plaintiff law firm | Jones Day | Law Firm | Representing Merck Sharp & Dohme, B.V.Search in Eureka ↗ |
| Defendant counsel | EDWARD J. DAUBER | Attorney | Counsel for USV Pvt., Ltd.Search in Eureka ↗ |
| Defendant law firm | CHIESA SHAHINIAN & GIANTOMASI PC | Law Firm | Representing USV Pvt., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s verdict is procedural rather than substantive: rather than adjudicating infringement or validity on the merits, it applies the doctrine of res judicata to import the Federal Circuit-affirmed Final Judgment from a prior consolidated action. The phrase ‘bound by the Federal Circuit’s decision … as to expiration date’ signals that the patent term question was conclusively resolved at appellate level and cannot be reopened. The equal cost allocation — atypical in ANDA cases where prevailing parties sometimes seek fees — suggests the court viewed this as a clean procedural resolution rather than a sanction-worthy dispute.
USRE044733E — Sugammadex injection for neuromuscular blockade reversal
USRE044733E is a United States reissue patent, corrected from application number US13/432742, covering sugammadex injection formulations — commercialised by Merck as Bridion® in 200 mg/2 mL and 500 mg/5 mL presentations. Sugammadex is a selective gamma-cyclodextrin derivative that encapsulates rocuronium and vecuronium, reversing neuromuscular blockade with a distinct mechanism of action from traditional cholinesterase inhibitors. A reissue patent arises when the patent holder seeks to correct errors in the original grant; its claims can be broadened or narrowed relative to the original, but it retains the original filing date priority.
Bridion® represents a significant revenue stream for Merck, and the reissue patent’s expiration date — now Federal Circuit-affirmed and binding on USV — is commercially critical for timing generic market entry. Any generic manufacturer filing an ANDA for sugammadex injection must navigate this patent’s term. The Federal Circuit affirmance of the consolidated judgment substantially raises the bar for invalidity challenges, as arguments previously raised in the consolidated litigation are likely foreclosed by res judicata, while arguments not raised may be subject to issue preclusion depending on the scope of prior pleadings.
Should you run an FTO against USRE044733E before launching sugammadex injection?
Any generic or biosimilar manufacturer, contract development and manufacturing organisation, or formulator considering a sugammadex injection product in the U.S. market should conduct a freedom-to-operate analysis against USRE044733E before filing an ANDA or scaling commercial production. This case confirms that the Federal Circuit has affirmed a final judgment tied to this reissue patent, and that at least one generic competitor (USV) has been bound by that ruling. Early FTO analysis can identify whether your specific formulation, dosage form, or manufacturing process falls within the enforceable claim scope.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of USRE044733E against your product specifications, flag related family members and continuation applications, and identify prior art that survived or was not raised in the consolidated litigation. Eureka can also surface the full litigation history of sugammadex patents across jurisdictions — helping your regulatory and commercial teams model launch timing risk against the Federal Circuit-affirmed expiration date with greater precision.
Run a freedom-to-operate analysis on USRE044733E to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical patent cases in the District of New Jersey
These cases involve pharmaceutical patent infringement actions in D.N.J., including ANDA disputes over branded injection products and reissue patent enforcement by innovator companies.
What this case signals for the pharmaceutical patent enforcement landscape
Merck’s use of res judicata and Federal Circuit precedent to resolve this case quickly sets a template for multi-defendant ANDA patent litigation.
Consolidated actions can resolve later cases without fresh merits review
Where a patentee has already obtained a Federal Circuit-affirmed judgment against one ANDA filer, that outcome can be deployed via res judicata to bind subsequent filers with sufficient legal connection. IP teams defending multiple generics should audit their exposure to prior consolidated actions before filing new ANDAs.
Reissue patents carry the same enforcement weight as original grants post-Federal Circuit affirmance
USRE044733E — a reissue of the original sugammadex patent — survived challenge at the Federal Circuit level and is now binding on USV. Reissue patents are sometimes perceived as more vulnerable to invalidity attacks; this case suggests that a Federal Circuit affirmance substantially insulates them from further challenge in related proceedings.
B.V. v USV — key questions answered
The case was resolved by consolidation with a prior related action. The New Jersey District Court entered a Modified Final Judgment holding that the Federal Circuit’s affirmance of the Final Judgment in the Consolidated Action operates as res judicata against both Merck and USV in this proceeding, binding both parties to the Federal Circuit-determined expiration date of the ‘733 patent. Each party was directed to bear its own fees and costs.
USRE044733E is a United States reissue patent (corrected from application US13/432742) held by Merck Sharp & Dohme, B.V. It covers sugammadex injection formulations, sold commercially as Bridion® in 200 mg/2 mL and 500 mg/5 mL presentations. Sugammadex is a selective neuromuscular blockade reversal agent used in anaesthesia. Reissue patents correct errors in original grants and retain the original filing date.
Res judicata (claim preclusion) prevents parties from re-litigating claims or issues that were conclusively decided in a prior action between the same parties or their privies. Here, the court found that the Federal Circuit’s affirmance of the Final Judgment in a prior Consolidated Action bound USV in this case, meaning USV could not independently re-litigate the expiration date of USRE044733E or the merits resolved in that prior proceeding.
The Federal Circuit had previously affirmed the Final Judgment in a Consolidated Action that addressed the ‘733 patent, including its expiration date. That appellate affirmance gave the prior judgment finality and precedential weight sufficient for the district court to apply res judicata in this subsequent action, binding USV without a fresh merits trial. This illustrates how Federal Circuit rulings in one ANDA action can foreclose re-litigation by related generic filers.
The case lasted 224 days from filing on January 23, 2025 to closure on September 4, 2025. This is notably faster than typical pharmaceutical patent litigation, which often runs two to four years to trial. The rapid closure is consistent with a procedural resolution: the court applied res judicata from a prior Federal Circuit-affirmed judgment rather than conducting a full merits review of infringement or validity, eliminating the need for discovery, claim construction, and trial.
PatSnap Eureka searches patents and litigation data to answer instantly.